A study explores the potential benefits of combining Sorafenib (SORA) with Fibroblast Growth Factor 21 (FGF21) in treating hepatocellular carcinoma (HCC). While SORA is commonly used, resistance can develop, leading to poor outcomes. FGF21 has shown promise in diabetes and lipid regulation, with potential anticancer effects. Researchers found that combining FGF21 with SORA increased sensitivity to HCC under hypoxia conditions, inhibiting cell growth and promoting apoptosis through the Smad3 pathway. This combination therapy could offer new possibilities for improving HCC treatment outcomes.
To Another Language
from source content
medicalxpress.com
Viktiga insikter från
by Higher Educa... på medicalxpress.com 02-26-2024
https://medicalxpress.com/news/2024-02-possibility-combination-therapy-sora-fgf21.htmlDjupare frågor